Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon–ribavirin combination therapy after 4 weeks of treatment

  • Hans Orlent, Isabelle Desombere, Bettina Hansen, Hans Van Vlierberghe, Bart Haagmans, Robert J. De Knegt, Solko W. Schalm, Geert Leroux-Roels, Harry L.A. Janssen
  • European Journal of Gastroenterology & Hepatology, September 2010, Wolters Kluwer Health
  • DOI: 10.1097/meg.0b013e32833ef6e3

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Professor Geert Leroux-Roels and Dr Bart L. Haagmans